Fluidigm Corp (FLDM)

3.76
NASDAQ : Health Care
Prev Close 3.76
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.52 / 9.65
Avg Volume 373.40K
Exchange NASDAQ
Shares Outstanding 38.51M
Market Cap 140.16M
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

FLDM: Insiders vs. Shorts

The most recent short interest data was recently released for the 07/14/2017 settlement date, and Fluidigm Corp is one of the most shorted stocks of the Russell 3000, based on 19.41 "days to cover" versus the median component at 6.16. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Fluidigm Introduces Immuno-Oncology Gene Expression Assay For Translational And Clinical Research

Fluidigm Introduces Immuno-Oncology Gene Expression Assay For Translational And Clinical Research

Advanta Immuno-Oncology Gene Expression Assay enables efficient screening of 170 highly informative genes involved in human checkpoint therapeutic response

Fluidigm Stock Sees Short Interest Move 13.7% Lower

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 355,914 share decrease in total short interest for Fluidigm Corp , to 2,244,445, a decrease of 13.69% since 05/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Fluidigm is Now Oversold (FLDM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Fluidigm Enters Oversold Territory (FLDM)

Fluidigm Enters Oversold Territory (FLDM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Short Interest Decreases By 11.3% For FLDM

Short Interest Decreases By 11.3% For FLDM

The most recent short interest data has been released for the 12/15/2016 settlement date, which shows a 291,762 share decrease in total short interest for Fluidigm Corp , to 2,285,483, a decrease of 11.32% since 11/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Fluidigm Reaches Analyst Target Price

Fluidigm Reaches Analyst Target Price

In recent trading, shares of Fluidigm Corp have crossed above the average analyst 12-month target price of $8.05, changing hands for $8.12/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

5 Stocks Under $10 Poised for Big Breakouts

5 Stocks Under $10 Poised for Big Breakouts

These under-$10 stocks are within range of triggering breakout trades. Here's how to play them.

Medtronic, Patterson Among Day's Biggest Losers, Trump Continues to Pressure Healthcare Sector

Medtronic, Patterson Among Day's Biggest Losers, Trump Continues to Pressure Healthcare Sector

President-elect Trump's vague healthcare policy has put the $3 trillion industry on edge.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies, including Hertz, are scooping up shares of their own stock lately.

Fluidigm Introduces High-Parameter Maxpar Mass Cytometry Panels For Immuno-Oncology Research

Fluidigm Introduces High-Parameter Maxpar Mass Cytometry Panels For Immuno-Oncology Research

A comprehensive and flexible approach to deeply profile T cell phenotypes and function in immune checkpoint response

Fluidigm And GenomOncology Partner To Provide Automated Oncology NGS Library Preparation With Molecular Interpretation And Reporting

Fluidigm And GenomOncology Partner To Provide Automated Oncology NGS Library Preparation With Molecular Interpretation And Reporting

Empowering clinical research laboratories to achieve new levels of productivity